XENE
Xenon Pharmaceuticals Inc. NASDAQ Listed Nov 5, 2014$36.54
-3.99%
vs $38.06
Mkt Cap $3.5B
52w Low $36.07
1.3% of range
52w High $72.66
50d MA $59.92
200d MA $53.28
P/E (TTM)
—
EV/EBITDA
—
P/B
5.0x
Debt/Equity
0.0x
ROE
-59.5%
P/FCF
-10.4x
RSI (14)
9.60
ATR (14)
$2.04
Beta
0.74
50d MA
$59.92
200d MA
$53.28
Avg Volume
1.5M
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
3650 Gilmore Way · Burnaby, BC V5G 4W8 · CA
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | AMC | -1.14 | -1.11 | +2.6% | 64.55 | -2.4% | -1.8% | +1.4% | -1.6% | +3.2% | -1.6% | — |
| May 7, 2026 | AMC | -1.17 | -1.17 | +0.0% | 56.00 | +0.2% | +0.8% | -1.2% | -1.4% | +1.6% | +0.2% | — |
| Feb 26, 2026 | AMC | -1.20 | -1.31 | -9.2% | 44.92 | +1.1% | -3.8% | -1.6% | +2.9% | -1.7% | -2.3% | — |
| Nov 3, 2025 | AMC | -1.16 | -1.15 | +0.9% | 41.12 | -3.4% | -4.9% | -1.1% | -0.9% | -0.1% | +0.4% | — |
| Aug 11, 2025 | AMC | -1.03 | -1.07 | -3.9% | 34.11 | +5.5% | +5.5% | +4.7% | +0.8% | +0.7% | -1.1% | — |
| May 12, 2025 | AMC | -0.94 | -0.83 | +11.7% | 35.85 | -8.5% | -17.4% | +0.5% | -0.6% | +2.4% | +2.2% | — |
| Feb 27, 2025 | AMC | -0.89 | -0.84 | +5.6% | 38.31 | -3.4% | -3.4% | -3.3% | +0.6% | +3.2% | +0.3% | — |
| Nov 12, 2024 | AMC | -0.82 | -0.81 | +0.7% | 43.39 | -0.7% | -3.3% | -0.5% | -4.6% | -3.8% | +1.4% | — |
| Aug 8, 2024 | AMC | -0.72 | -0.75 | -4.2% | 41.01 | -10.0% | -3.2% | -2.1% | -0.1% | -0.3% | -1.2% | — |
| May 9, 2024 | AMC | -0.69 | -0.62 | +10.1% | 42.49 | -4.1% | -4.6% | -0.1% | +0.2% | -0.3% | -0.3% | — |
| Feb 29, 2024 | AMC | -0.76 | -0.64 | +15.8% | 47.20 | +5.3% | -0.8% | -1.9% | +0.1% | -0.1% | +0.4% | — |
| Nov 8, 2023 | AMC | -0.75 | -0.73 | +2.7% | 32.15 | +4.0% | -6.7% | -3.9% | +3.0% | +0.2% | -2.0% | — |
| Aug 9, 2023 | AMC | -0.69 | -0.72 | -4.3% | 35.45 | +2.2% | +8.3% | -1.8% | -0.4% | -0.5% | -2.4% | — |
| May 9, 2023 | AMC | -0.62 | -0.63 | -1.6% | 43.54 | -4.0% | -5.5% | -0.4% | -2.0% | +3.9% | -1.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 18 | Deutsche Bank | Downgrade | Buy → Hold | $46 | $57.35 | $44.02 | -23.2% | -30.7% | -1.9% | +0.3% | -6.5% | +4.1% |
| Mar 16 | Wedbush | Maintains | Outperform → Outperform | — | $55.23 | $55.00 | -0.4% | -1.0% | +1.0% | -0.2% | +0.2% | -0.4% |
| Mar 10 | Wells Fargo | Maintains | Overweight → Overweight | — | $62.76 | $63.26 | +0.8% | -3.4% | -2.6% | -1.9% | -4.6% | -1.0% |
| Mar 10 | Wedbush | Maintains | Outperform → Outperform | — | $62.76 | $63.26 | +0.8% | -3.4% | -2.6% | -1.9% | -4.6% | -1.0% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $62.76 | $63.26 | +0.8% | -3.4% | -2.6% | -1.9% | -4.6% | -1.0% |
| Mar 10 | Deutsche Bank | Maintains | Buy → Buy | — | $62.76 | $63.26 | +0.8% | -3.4% | -2.6% | -1.9% | -4.6% | -1.0% |
| Mar 9 | Baird | Maintains | Outperform → Outperform | — | $41.94 | $60.56 | +44.4% | +49.6% | -3.4% | -2.6% | -1.9% | -4.6% |
| Mar 9 | Needham | Maintains | Buy → Buy | — | $41.94 | $60.56 | +44.4% | +49.6% | -3.4% | -2.6% | -1.9% | -4.6% |
| Feb 27 | Wells Fargo | Maintains | Overweight → Overweight | — | $44.92 | $45.40 | +1.1% | -3.8% | -1.6% | +2.9% | -1.7% | -2.3% |
| Feb 27 | Needham | Maintains | Buy → Buy | — | $44.92 | $45.40 | +1.1% | -3.8% | -1.6% | +2.9% | -1.7% | -2.3% |
| Jan 9 | JP Morgan | Maintains | Overweight → Overweight | — | $41.22 | $41.55 | +0.8% | +2.3% | -2.2% | -2.1% | +3.0% | -2.0% |
| Dec 11 | Wells Fargo | Maintains | Overweight → Overweight | — | $43.44 | $43.44 | +0.0% | +0.5% | +0.9% | -1.0% | -1.4% | +0.0% |
| Nov 18 | JP Morgan | Maintains | Overweight → Overweight | — | $40.61 | $40.60 | -0.0% | +0.0% | +0.1% | -0.9% | +2.2% | +2.2% |
| Nov 4 | RBC Capital | Maintains | Outperform → Outperform | — | $41.12 | $39.74 | -3.4% | -4.9% | -1.1% | -0.9% | -0.1% | +0.4% |
| Nov 4 | Needham | Maintains | Buy → Buy | — | $41.12 | $39.74 | -3.4% | -4.9% | -1.1% | -0.9% | -0.1% | +0.4% |
| Nov 4 | Wells Fargo | Maintains | Overweight → Overweight | — | $41.12 | $39.74 | -3.4% | -4.9% | -1.1% | -0.9% | -0.1% | +0.4% |
| Oct 7 | Chardan Capital | Maintains | Buy → Buy | — | $39.55 | $39.16 | -1.0% | -1.0% | +0.2% | +5.2% | -4.0% | +0.9% |
| Sep 2 | RBC Capital | Maintains | Outperform → Outperform | — | $38.71 | $38.89 | +0.5% | +1.5% | -1.2% | -0.5% | +1.5% | -2.6% |
| Aug 12 | Chardan Capital | Maintains | Buy → Buy | — | $34.11 | $36.00 | +5.5% | +5.5% | +4.7% | +0.8% | +0.7% | -1.1% |
| Aug 12 | RBC Capital | Maintains | Outperform → Outperform | — | $34.11 | $36.00 | +5.5% | +5.5% | +4.7% | +0.8% | +0.7% | -1.1% |
| Aug 12 | Wedbush | Maintains | Outperform → Outperform | — | $34.11 | $36.00 | +5.5% | +5.5% | +4.7% | +0.8% | +0.7% | -1.1% |
| Jun 13 | RBC Capital | Maintains | Outperform → Outperform | — | $32.80 | $32.40 | -1.2% | -0.1% | -2.3% | -1.0% | +0.6% | +0.5% |
| May 13 | Chardan Capital | Maintains | Buy → Buy | — | $35.85 | $32.81 | -8.5% | -17.4% | +0.5% | -0.6% | +2.4% | +2.2% |
| May 13 | Needham | Maintains | Buy → Buy | — | $35.85 | $32.81 | -8.5% | -17.4% | +0.5% | -0.6% | +2.4% | +2.2% |
| May 13 | RBC Capital | Maintains | Outperform → Outperform | — | $35.85 | $32.81 | -8.5% | -17.4% | +0.5% | -0.6% | +2.4% | +2.2% |
| May 13 | Wells Fargo | Maintains | Overweight → Overweight | — | $35.85 | $32.81 | -8.5% | -17.4% | +0.5% | -0.6% | +2.4% | +2.2% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $35.85 | $32.81 | -8.5% | -17.4% | +0.5% | -0.6% | +2.4% | +2.2% |
| Apr 17 | Goldman Sachs | Maintains | Buy → Buy | — | $33.78 | $33.71 | -0.2% | +3.9% | -1.2% | +5.9% | +2.3% | +1.6% |
| Feb 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $39.73 | $39.59 | -0.4% | -3.4% | -1.9% | +3.9% | -2.0% | -3.4% |
| Dec 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $42.97 | $42.62 | -0.8% | -8.2% | +1.5% | +3.1% | -0.1% | -4.7% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $43.39 | $43.08 | -0.7% | -3.3% | -0.5% | -4.6% | -3.8% | +1.4% |
| Nov 13 | Needham | Maintains | Buy → Buy | — | $43.39 | $43.08 | -0.7% | -3.3% | -0.5% | -4.6% | -3.8% | +1.4% |
| Sep 3 | RBC Capital | Maintains | Outperform → Outperform | — | $40.34 | $40.22 | -0.3% | -0.5% | +1.0% | -1.7% | -3.5% | +0.4% |
| Aug 12 | Needham | Maintains | Buy → Buy | — | $39.70 | $39.36 | -0.9% | -2.1% | -0.1% | -0.3% | -1.2% | -0.9% |
| Aug 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $41.01 | $36.92 | -10.0% | -3.2% | -2.1% | -0.1% | -0.3% | -1.2% |
| Aug 9 | Wedbush | Maintains | Outperform → Outperform | — | $41.01 | $36.92 | -10.0% | -3.2% | -2.1% | -0.1% | -0.3% | -1.2% |
| Jun 18 | RBC Capital | Maintains | Outperform → Outperform | — | $36.60 | $36.71 | +0.3% | -1.0% | +2.3% | +1.1% | -0.2% | -1.1% |
| May 10 | Citigroup | Maintains | Buy → Buy | — | $42.49 | $40.76 | -4.1% | -4.6% | -0.1% | +0.2% | -0.3% | -0.3% |
| May 10 | Needham | Maintains | Buy → Buy | — | $42.49 | $40.76 | -4.1% | -4.6% | -0.1% | +0.2% | -0.3% | -0.3% |
| May 10 | Wedbush | Maintains | Outperform → Outperform | — | $42.49 | $40.76 | -4.1% | -4.6% | -0.1% | +0.2% | -0.3% | -0.3% |
| Apr 12 | Needham | Maintains | Buy → Buy | — | $42.97 | $42.67 | -0.7% | -3.9% | +0.0% | +0.4% | +0.3% | -3.2% |
| Apr 10 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $43.03 | $42.58 | -1.0% | -1.4% | +1.3% | -3.9% | +0.0% | +0.4% |
| Mar 1 | RBC Capital | Maintains | Outperform → Outperform | — | $47.20 | $49.70 | +5.3% | -0.8% | -1.9% | +0.1% | -0.1% | +0.4% |
| Mar 1 | Needham | Maintains | Buy → Buy | — | $47.20 | $49.70 | +5.3% | -0.8% | -1.9% | +0.1% | -0.1% | +0.4% |
| Mar 1 | Wedbush | Maintains | Outperform → Outperform | — | $47.20 | $49.70 | +5.3% | -0.8% | -1.9% | +0.1% | -0.1% | +0.4% |
| Jan 2 | BofA Securities | Maintains | Buy → Buy | — | $46.06 | $45.49 | -1.2% | -2.5% | -1.6% | +4.1% | -1.1% | +5.2% |
| Dec 18 | Stifel | Maintains | Buy → Buy | — | $41.41 | $41.65 | +0.6% | -0.6% | +2.1% | -2.4% | +1.3% | +7.5% |
| Nov 28 | RBC Capital | Maintains | Outperform → Outperform | — | $34.12 | $34.42 | +0.9% | +3.3% | -4.2% | +8.4% | +0.6% | +2.6% |
| Nov 9 | Wedbush | Maintains | Outperform → Outperform | — | $32.15 | $33.42 | +4.0% | -6.7% | -3.9% | +3.0% | +0.2% | -2.0% |
| Sep 22 | RBC Capital | Maintains | Outperform → Outperform | — | $35.76 | $35.76 | +0.0% | -1.6% | +0.4% | -0.8% | +0.2% | +0.7% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 5, 2026 | Cannon Gillian | — | Sell | 1,190 | $53.14 | $63K | 1,455 | +3.09% | +0.58% |
| Jun 5, 2026 | PATOU GARY | — | Sell | 1,322 | $53.14 | $70K | 24,896 | +3.09% | +0.58% |
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Xenon Pharmaceuticals' leadership transition could signal strategic shifts in pipeline priorities or commercialization strategy, warranting investor attention to upcoming guidance and management commentary on R&D direction.
Apr 13
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
I cannot provide a meaningful analysis because the filing content appears corrupted or incomplete, containing only contact information and encoded graphics without substantive business disclosures needed to assess investment impact.
Mar 13
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Underwriting / Securities
Xene Therapeutics raised $707.7 million in a securities offering, providing substantial capital for clinical development and operations, which reduces near-term dilution risk and strengthens the biotech's runway for advancing pipeline programs.
Mar 12
8-K · 7.01
! Medium
Xenon Pharmaceuticals Inc -- 8-K 7.01: Regulation FD Disclosure
Xenon Pharmaceuticals disclosed topline data results via investor presentation on March 9, 2026, signaling potential progress in clinical development that management intends to discuss with investors and analysts.
Mar 9
8-K · 8.01
!! High
Xenon Pharmaceuticals Inc -- 8-K 8.01: Material Event / Announcement
Xenon Pharmaceuticals terminated its prior offering after raising $291 million in share sales, replacing it with a new prospectus supplement for continued equity fundraising flexibility.
Feb 27
8-K · 7.01
! Medium
Xenon Pharmaceuticals Inc -- 8-K 7.01: Regulation FD Disclosure
Xenon Pharmaceuticals expanded its investor communication channels to include social media platforms X, LinkedIn, and Facebook, enabling broader real-time access to company updates and product development information.
Feb 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 10,818,491 | $629M | Added | Mar 2026 |
| 2 | Blackrock, Inc. | 7,522,482 | $454M | New | Jun 2026 |
| 3 | Avoro Capital Advisors Llc | 5,777,777 | $336M | Added | Mar 2026 |
| 4 | Janus Henderson Group Plc | 4,175,982 | $243M | New | Mar 2026 |
| 5 | Citadel Advisors Llc | 2,802,484 | $169M | Reduced | Jun 2026 |
| 6 | Jpmorgan Chase & Co | 1,923,610 | $107M | Added | Mar 2026 |
| 7 | Two Sigma Investments, Lp | 1,642,848 | $99M | Added | Jun 2026 |
| 8 | Deerfield Management Company, L.p. | 1,615,696 | $94M | Added | Mar 2026 |
| 9 | Braidwell Lp | 1,825,076 | $82M | Reduced | Dec 2025 |
| 10 | Siren, L.l.c. | 1,318,564 | $80M | New | Jun 2026 |
| 11 | Bnp Paribas Asset Management Holding S.a. | 1,290,731 | $78M | Reduced | Jun 2026 |
| 12 | Alyeska Investment Group, L.p. | 1,299,469 | $76M | New | Mar 2026 |
| 13 | Franklin Resources Inc | 1,280,577 | $74M | Added | Mar 2026 |
| 14 | Pictet Asset Management Holding Sa | 1,187,723 | $72M | Added | Jun 2026 |
| 15 | Nuveen, Llc | 993,126 | $60M | Added | Jun 2026 |
| 16 | Capital World Investors | 840,072 | $49M | Added | Mar 2026 |
| 17 | Vanguard Portfolio Management Llc | 749,651 | $45M | Added | Jun 2026 |
| 18 | Mpm Bioimpact Llc | 588,706 | $34M | Added | Mar 2026 |
| 19 | Tudor Investment Corp Et Al | 545,387 | $33M | Added | Jun 2026 |
| 20 | Northern Trust Corp | 527,783 | $31M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$3.53B
Enterprise Value
$2.35B
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.23x
P/B
4.98x
P/S
—
P/FCF
-10.35x
EV/EBITDA
—
Shares Out
79.3M
Financials (TTM)
Revenue
$0
Net Income
-$409.2M
EBITDA
-$416.8M
Free Cash Flow
-$279.9M
Op Cash Flow
-$279.1M
EPS Basic
$-4.36
EPS Diluted
$-4.74
EPS Forward
$-4.79
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$981.7M
Total Liab.
$399.9M
Total Equity
$581.8M
Cash
$548.9M
LT Debt
$0
Book Value/Sh
$7.34
Debt/Equity
0.01x
Current Ratio
13.42
Quick Ratio
13.42
Returns & Growth
ROE
-59.5%
ROA
-54.6%
ROIC
-39.6%
Rev Growth YoY
+0.0%
EPS Growth YoY
-44.9%
Price Returns
2W
-35.3%
1M
-37.0%
3M
-33.0%
6M
-31.5%
12M
+4.2%
Technicals
52W High
$72.66
52W Low
$36.07
50d MA
$59.92
200d MA
$53.28
RSI (14)
9.60
ATR (14)
$2.04
Beta
0.74
Avg Volume
1.5M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$80.20
High
$100.00
Low
$44.00
Median
$89.50
Data updated apr 27, 2026 10:29am
· Source: financialmodelingprep.com